Patients with Low Pulmonary Vascular Resistance May Benefit from Complex Procedure Usually Offered Only for Patients with Pulmonary Hypertension

Newswise — ATS 2014, SAN DIEGO ─ Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don’t have severe pulmonary hypertension, according to University of California, San Diego, researchers.

The study was presented at the 2014 American Thoracic Society International Conference.

UCSD pioneered PTE in the 1970s for patients who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). During PTE, surgeons put a patient on a heart-lung machine, cool the body to reduce its need for oxygen and then turn the machine off for up to 20 minutes so they can remove clots and scar tissue from the patient’s arteries. Because of the procedure’s complexity, it has been used, until recently, only to help patients whose pulmonary thromboembolic disease causes severe hypertension and has not responded to other therapies.

“Over the past five years, an increasing number of patients with symptomatic chronic thromboembolic disease, without severe pulmonary hypertension, are being offered and choosing to undergo the surgery, said lead investigator Daniel Crouch, MD, a third-year pulmonary and critical care fellow at UCSD. “These patients have symptoms that create a major burden in their lives. However, given that they do not have severe pulmonary hypertension and cardiac dysfunction, the benefits of the surgery must greatly outweigh the risks. “

In a retrospective chart review of patients who underwent PTE at UCSD between July 2010 and June 2013, Crouch found that 64 subjects had pre-operative pulmonary resistance values (PVRs) less than 300 dyn∙/cm5 and 355 patients had PVRs above 300dyn∙/cm5. (The value is used at UCSD as a guide to identify patients with severe and non-severe pulmonary hypertension.) In the UCSD study, both groups had similar mean age and gender composition, while the body mass index (32.57 vs 30.18) was higher in the low PVR group.

Crouch and his colleagues found that those in the low PVR group had lower mortality (0 vs. 1.1%) and fewer complications, including delirium (7.8% vs. 14.9%), pneumonia/tracheobronchitis (6.3% vs. 15.5%), and a statistically significant lower rate of reperfusion lung injury (7.8% vs. 25.9%), The low PVR group also experienced statistically significant recoveries, with less time spent on the ventilator (1.7 vs. 3.2 days), in the ICU (4 vs. 5.8 days) and in the hospital (13 vs. 16.3 days).

Anecdotally, Crouch added, patients in the low PVR group showed “great benefit” in follow up visits. Nonetheless, the program is conducting a follow-up study to evaluate formally improvement in their functional status and quality of life. With higher (BMI) and a higher rate of simultaneous coronary artery bypass grafting (9.4% vs. 15.5%), he said, those in the low group may have other factors that contribute to their symptoms before surgery.“Although pulmonary thromboendarterectomy is the procedure of choice for CTEPH, there are important questions to answer before it can be considered the treatment of choice in the low PVR patient population,” Crouch said. “As with anything we offer patients, we want to prove it’s the best therapy.”###

* Please note that numbers in this release may differ slightly from those in the abstract. Many of these investigations are ongoing; the release represents the most up-to-date data available at press time.

Abstract 54362Pulmonary Thromboendarterectomy In Patients With Chronic Pulmonary Thromboembolic Disease And Low Preoperative Pulmonary Vascular ResistanceType: Scientific AbstractCategory: 18.08 - Pulmonary Embolism: Acute and Chronic (PC)Authors: D.R. Crouch, P.F. Fedullo, W.R. Auger; UC San Diego - San Diego, CA/US

Abstract BodyRationale: Chronic thromboembolic pulmonary hypertension (CTEPH) is potentially reversible with pulmonary thromboendarterectomy (PTE). Classically, this surgery has been reserved for patients with significantly elevated pulmonary pressures. More recently, a growing number of patients are being diagnosed with symptomatic chronic pulmonary thromboembolic disease without evidence of severe pulmonary hypertension. We reviewed our experience with patients with PVRs less than 300 compared to the patients with higher pre-operative PVRs at UCSD.Methods: This was a retrospective chart review of patients with chronic pulmonary thromboembolic disease who underwent PTE surgery between July, 2010 through June, 2013. The low PVR group includes 64 subjects with a PVR less than or equal to 300 dyn•s/cm5 (mean PVR 209) and the high PVR group includes 355 subjects with pre-operative PVR above 300 dyn•s/cm5 (mean PVR 756). Patient demographics, pre-operative and post-operative hemodynamics, hospital and ICU length of stay, ventilator days, complication rates, associated procedures performed, and mortality were reviewed.Results: Both groups had a similar mean age, gender composition, and BMI. The low PVR group spent less time on the ventilator (1.7 vs. 3.2 days), less time in the ICU (4 vs. 5.8 days), and less time in the hospital (13 vs. 16.3 days) compared to the high PVR group. There were fewer overall complications in the low PVR group, most notably lower rates of reperfusion lung injury (7.8% vs. 25.9%), delirium (7.8% vs. 14.9%), and pneumonia/tracheobronchitis (6.3% vs. 15.5%). There was a high rate of postoperative pericardial effusion in the low PVR group (10.9% vs. 5.1%). Low PVR patients had a higher rate of simultaneous CABG (9.4% vs. 7.0%) and a lower rate of PFO closure at the time of surgery (12.5% vs. 22%). Mortality was 0% in the low PVR group and 1.1% in the high PVR group.Conclusions: For patients with symptomatic chronic thromboembolic disease and a PVR less than 300, surgical intervention carries a lower mortality risk, fewer complications, and faster recovery with shorter ICU and hospital stays as compared to those patients with PVRs over 300. These data suggest that surgical intervention is a reasonable and relatively safe therapeutic option in this patient population. Further studies are currently ongoing to evaluate this group for clinical improvements in functional status and quality of life after surgery.